Halozyme Therapeutics (NASDAQ:HALO) Issues FY25 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of $4.95-$5.35 for the period, compared to the consensus EPS estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Halozyme Therapeutics Trading Up 5.0 %

Shares of HALO stock opened at $53.76 on Thursday. Halozyme Therapeutics has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The stock’s fifty day moving average is $50.10 and its two-hundred day moving average is $54.00. The firm has a market capitalization of $6.84 billion, a P/E ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. JMP Securities boosted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Piper Sandler lifted their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. HC Wainwright restated a “buy” rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a report on Monday, December 30th. Finally, JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.11.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $9,254,244.56. The trade was a 5.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.